title: Pagoclone Indevus.
abstract: Pagoclone is a cyclopyrrolone GABAA receptor modulator under development by Indevus for the potential treatment of panic and anxiety disorders. Indevus initiated phase II/III trials in November 1996. Pfizer had initiated a phase III trial for panic disorder in August 2000 but discontinued development of the compound in June 2002.
authors.affiliation: School of Biomedical Sciences, Leeds University, Leeds, LS2 9JT, UK. a.n.bateson@leeds.ac.uk
authors.forename: Alan
authors.initials: A
authors.lastname: Bateson
mesh_terms: D000818:Animals; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D054833:Isoindoles; D009287:Naphthyridines / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D016584:Panic Disorder / Q000188:drug therapy; D013329:Structure-Activity Relationship
chemical_list: D014151:Anti-Anxiety Agents; D054833:Isoindoles; D009287:Naphthyridines; C447412:pagoclone